公开(公告)号：US20180238895A1

公开(公告)日：2018-08-23

申请号：US15870449

申请日：2018-01-12

申请人： BioAlliance C.V.

发明人： Rong-Hwa LIN ,  Leewen LIN ,  Shih-Yao LIN ,  Shu-Hua LEE

IPC分类号： G01N33/574 ,  C07K16/30 ,  C07K16/28 ,  A61K39/395 ,  A61K39/00

CPC分类号： G01N33/57492 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/3007 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  G01N2333/70503 ,  G01N2333/70596

摘要： The present invention provides novel antibodies specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells, but do not specifically bind to a CD43 expressed by a leukocyte or by a Jurkat cell, and is capable of inducing apoptosis of the nonhematopoietic cancer cell after binding to the epitope on cell surface of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function, wherein the epitope comprises a carbohydrate structure and the binding of the antibody to the epitope is inhibited by a carbohydrate comprising a Lea structure, a Lea-lactose structure, a LNDFH II structure, or a LNT structure. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.

公开(公告)号：US20130177579A1

公开(公告)日：2013-07-11

申请号：US13734056

申请日：2013-01-04

申请人： BIOALLIANCE C.V.

发明人： Shih-Yao LIN ,  Leewen LIN ,  Yu-Ying TSAI ,  Chiu-Chen HUANG ,  Feng-Lin CHIANG ,  Yu-Chi HSIEH

IPC分类号： C07K16/28

CPC分类号： C07K16/28 ,  C07K16/2881 ,  C07K16/30 ,  C07K2317/73 ,  C07K2317/77

摘要： The present disclosure relates to antibodies that recognize a carbohydrate on transferrin receptor expressed by nonhematopoietic tumor or cancer cells and uses thereof.

摘要翻译： 本公开涉及识别由非造血肿瘤或癌细胞表达的转铁蛋白受体上的碳水化合物的抗体及其用途。

公开(公告)号：US20160139131A1

公开(公告)日：2016-05-19

申请号：US14918490

申请日：2015-10-20

申请人： BioAlliance C.V.

发明人： Rong-Hwa LIN ,  Leewen LIN ,  Shih-Yao LIN ,  Shu-Hua LEE

IPC分类号： G01N33/574 ,  C07K16/30 ,  C07K16/28

CPC分类号： G01N33/57492 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/3007 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  G01N2333/70503 ,  G01N2333/70596

摘要： The present invention provides novel antibodies specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells, but do not specifically bind to a CD43 expressed by a leukocyte or by a Jurkat cell, and is capable of inducing apoptosis of the nonhematopoietic cancer cell after binding to the epitope on cell surface of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function, wherein the epitope comprises a carbohydrate structure and the binding of the antibody to the epitope is inhibited by a carbohydrate comprising a Lea structure, a Lea-lactose structure, a LNDFH II structure, or a LNT structure. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.

摘要翻译： 本发明提供了特异性结合在非造血癌细胞上表达的CD43和CEA上的表位的新型抗体，但不特异性结合由白细胞或Jurkat细胞表达的CD43，并能够诱导非造血细胞的细胞凋亡 在不存在细胞毒素缀合和免疫效应子功能的情况下在与非造血细胞癌细胞的细胞表面上的表位结合之后，其中所述表位包含碳水化合物结构，并且抗体与表位的结合被包含Lea结构的碳水化合物所抑制， Lea-lactose结构，LNDFH II结构或LNT结构。 此外，本发明还提供本文所述的抗体用于诊断和治疗目的的用途。

公开(公告)号：US20140105899A1

公开(公告)日：2014-04-17

申请号：US14035731

申请日：2013-09-24

申请人： BioAlliance C.V.

发明人： Shih-Yao LIN ,  Leewen LIN ,  Yu-Ying TSAI

IPC分类号： C07K16/28 ,  C07K16/30

CPC分类号： C07K16/2896 ,  C07K16/3007 ,  C07K16/3076 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/73

摘要： The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.

摘要翻译： 本发明提供抗体（例如嵌合和人源化抗体）特异性结合在非造血癌细胞上表达的CD43和CEA上的表位。 此外，本发明还提供本文所述的抗体用于诊断和治疗目的的用途。